Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan

Pharmacogenomics

Volumn 8, Issue 4, 2007, Pages 319-327

  Vincenzi, Bruno ^a   Santini, Daniele ^a   Russo, Antonio ^b   Gavasci, Michele ^a   Battistoni, Fabrizio ^a   Dicuonzo, Giordano ^a   Rocci, Laura ^a   Rosaria, Valerio Maria ^b   Gebbia, Nicola ^b   Tonini, Giuseppe ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

Angiogenesis; Cetuximab; Colorectal cancer; Irinotecan; Survival; Vascular endothelial growth factor

Indexed keywords

ANTIEMETIC AGENT; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; LIVER METASTASIS; LOADING DRUG DOSE; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; METASTASIS POTENTIAL; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PREDICTION; PROGNOSIS; SKIN TOXICITY; STATISTICAL SIGNIFICANCE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34247170045     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.4.319     Document Type: Article

References (43)

1. Grothey A, Schmoll HJ: New chemotherapy approaches in colorectal cancer. Curr. Opin. Oncol. 13, 275-286 (2001).
2. Venook A: Critical evaluation of current treatments in metastatic colorectal cancer. Oncologist 10, 250-261 (2005).
3. Baselga J: Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 7, S2-S8 (2002).
4. Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19, 183-232 (1995).
5. Woodburn JR: The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol. Ther. 82, 241-250 (1999).
6. Nicholson RI, Gee JM, Harper ME: EGFR and cancer prognosis. Eur. J. Cancer 37, S9-S15 (2001).
7. Mendelsohn J, Baselga J: The EGF receptor family as targets for cancer therapy. Oncogene 19, 6550-6565 (2000).
8. Arteaga CL: Epidermal growth factor receptor dependence in human tumors: more than just expression. Oncologist 7, 31-39 (2002).
9. Peng D, Fan Z, Lu Y et al.: Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res. 56, 3666-3669 (1996).
10. Vallbohmer D, Lenz HJ: Epidermal growth factor receptor as a target for chemotherapy. Clin. Colorectal Cancer 5, S19-S27 (2005).
11. Perrotte P, Matsumoto T, Inoue K et al.: Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res. 5, 257-265 (1999).
12. Karashima T, Sweeney P, Slaton JW et al.: Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgeni-ndependent prostate cancer growing orthotopically innude mice. Clin. Cancer Res. 8, 1253-1264 (2002).
13. Mendelsohn J: Blockade of receptors for growth factors: an anticancer therapy - the fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture. Clin. Cancer Res. 6, 747-753 (2000).
14. Milas L, Fan Z, Andratschke NH, Ang KK: Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int. J. Radiat. Oncol. Biol. Phys. 58, 966-971 (2004).
15. Bruns CJ, Harbison MT, Davis DW et al.: Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin. Cancer Res. 6, 1936-1948 (2000).
16. Inoue K, Slaton JW, Perrotte P et al.: Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin. Cancer Res. 6, 4874-4884 (2000)
17. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ: Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin. Cancer Res. 8, 994-1003 (2002).
18. Vincenzi B, Santini D, Russo A et al.: Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients. Ann. Oncol. 17, 835-841 (2006).
19. Therasse P, Arbuck SG, Eisenhauer EA et al.: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. 92, 205-216 (2000).
20. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53, 457-481 (1958).
21. Peto R, Pike MC, Armitage P et al.: Design and analysis of randomised clinical trials requiring prolonged observation of each patient. Br. J. Cancer 35, 1-39 (1977).
22. Cox DR: Regression models and life tables. J. R. Stat. Soc. 34, 187-220 (1972).
23. Petit AM, Rak J, Hung WC et al.: Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol. 151, 1523-1530 (1997).
24. Masui H, Kawamoto T, Sato JD et al.: Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 44, 1002-1007 (1984).
25. Radinsky R, Risin S, Fan D et al.: Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin. Cancer Res. 1, 19-31 (1995).
26. Dinney CPN, Parker C, Dong A et al.: Therapy of human transitional cell carcinoma of the bladder by oral administration of epidermal growth factor receptor protein tyrosine kinase inhibitor 4,5-dianilinophthalimide. Clin. Cancer Res. 3, 161-168 (1997).
27. Fan Z, Masui H, Atlas I, Mendelsohn J: Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 of anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 53, 4322-4238 (1993).
28. Kizaka-Kondoh S, Sato K, Tamura K, Nojima H, Okayama H: Raf-1 protein kinase is an integral component of the oncogenic signal cascade shared by epidermal growth factor and platelet-derived growth factor. Mol. Cell. Biol. 12, 5078-5086 (1992).
29. Chung LW: Implications of stromal-epithelial interaction in human prostate cancer growth, progression and differentiation. Semin. Cancer Biol. 4, 183-192 (1993).
30. Zak DE, Hao H, Vadigepalli R et al.: Systems analysis of circadian time-dependent neuronal epidermal growth factor receptor signaling. Genome Biol. 7(6), R48 (2006).
31. Goldman CK, Kim J, Wong WL et al.: Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol. Biol. Cell 4, 121-133 (1993).
32. Akagi M, Kawaguchi M, Liu W et al.: Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells. Br. J. Cancer 88, 796-802 (2003).
33. Parikh AA, Liu WB, Fan F et al.: Expression and regulation of the novel vascular endothelial growth factor receptor neuropilin-1 by epidermal growth factor in human pancreatic carcinoma. Cancer 98, 720-729 (2003).
34. Vallbohmer D, Zhang W, Gordon M et al.: Molecular determinants of cetuximab efficacy. J. Clin. Oncol. 23, 3536-3544 (2005).
35. Tonra JR, Deevi DS, Corcoran E et al.: Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin. Cancer Res. 12, 2197-2207 (2006).
36. Chung KY, Shia J, Kemeny NE et al.: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. 23(9), 1803-1810 (2005).
37. Vincenzi B, Santini D, Tonini G: New issues on cetuximab mechanism of action in epidermal growth factor receptor-negative colorectal cancer: the role of vascular endothelial growth factor. J. Clin. Oncol. 24(12), 1957 (2006).
38. Bocci G, Man S, Green SK et al.: Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer Res. 64(18), 6616-6625 (2004).
39. Cunningham D, Humblet Y, Siena S et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337-345 (2004).
40. Vincenzi B, Santini D, Rabitti C et al.: Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre Phase II trial. Br. J. Cancer 94, 792-797 (2006).
41. Gebbia V, Del Prete S, Borsellino N et al.: Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience. Clin. Colorectal Cancer 5(6), 422-428 (2006).
42. George ML, Eccles SA, Tutton MG, Abulafi AM, Swift RI: Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin. Cancer Res. 6, 3147-3152 (2000).
43. Gunsilius E, Petzer A, Stockhammer G et al.: Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology 58, 169-174 (2000).